Efficiently generating evidence of clinical utility is a major challenge for ensuring clinical adoption of valuable diagnostics. A new approach to reimbursement in the United States offers a balance between evidence and incentives for molecular diagnostic tests.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
42 U.S.C. § 1395y(a)(1)(A).
Tunis, S.R. N. Engl. J. Med. 350, 2196–2198 (2004).
Potti, A. et al. N. Engl. J. Med. 355, 570–580 (2006).
Acharya, C.R. et al. J. Am. Med. Assoc. 299, 1574–1587 (2008).
Paik, S. et al. J. Clin. Oncol. 24, 3726–3734 (2006).
Evans, W.E. & McLeod, H.L. N. Engl. J. Med. 348, 538–549 (2003).
Bild, A.H. et al. Nature 439, 353–357 (2006).
Rieder, M.J. et al. N. Engl. J. Med. 352, 2285–2293 (2005).
Liu, R. et al. N. Engl. J. Med. 356, 217–226 (2007).
Glickman, S.W. et al. N. Engl. J. Med. 360, 816–823 (2009).
Modan, B. et al. N. Engl. J. Med. 345, 235–240 (2001).
Anonymous. (USDHHS, CMS, Baltimore, MD, USA) <https://www.cms.hhs.gov/mcd/ncpc_view_document.asp?id=8> (Accessed May 14, 2008).
Kolata, G. Medicare covering new treatments, but with a catch. New York Times (5 November, 2004).
Tunis, S.R. & Pearson, S.D. Health Aff. 25, 1218–1230 (2006).
Reed, S.D., Shea, A.M. & Schulman, K.A. J. Gen. Intern. Med. 23 Suppl 1, 50–56 (2008).
Ackerly, D.C., Valverde, A.M., Diener, L.W., Dossary, K.L. & Schulman, K.A. Health Aff. 28, w68–w75 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.A.S. received research support from Actelion Pharmaceuticals, Allergan, Amgen, Astellas Pharma, Bristol-Myers Squibb, The Duke Endowment, Genentech, Inspire Pharmaceuticals, Johnson & Johnson, Kureha Corporation, LifeMasters Supported SelfCare, Medtronic, Merck & Co., Nabi Biopharmaceuticals, National Patient Advocate Foundation, North Carolina Biotechnology Center, NovaCardia, Novartis, OSI Eyetech, Pfizer, Sanofi-aventis, Scios, Tengion, Theravance, Thomson Healthcare and Vertex Pharmaceuticals; personal income for consulting from McKinsey & Company and the National Pharmaceutical Council; had equity in Alnylam Pharmaceuticals; had equity in and served on the board of directors of Cancer Consultants, Inc; and had equity in and serving on the executive board of Faculty Connection. K.A.S. has made available online a detailed listing of financial disclosures (http://www.dcri.duke.edu/research/coi.jsp). S.R.T. is an employee of the Center for Medical Technology Policy (CMPT), a nonprofit policy and research center that works on issues of comparative effectiveness research and coverage with evidence development. CMPT receives funding from a range of health plans, life sciences companies, foundations and government grants.
Rights and permissions
About this article
Cite this article
Schulman, K., Tunis, S. A policy approach to the development of molecular diagnostic tests. Nat Biotechnol 28, 1157–1159 (2010). https://doi.org/10.1038/nbt1110-1157
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1110-1157
This article is cited by
-
Overhauling the reimbursement system for molecular diagnostics
Nature Biotechnology (2011)